FRA:0QF - Deutsche Boerse Ag - US60770K1079 - Common Stock - Currency: EUR
FRA:0QF (3/7/2025, 7:00:00 PM)
34.185
+2.21 (+6.89%)
The current stock price of 0QF.DE is 34.185 EUR. In the past month the price increased by 7.3%. In the past year, price decreased by -62.85%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
4AB.DE | ABBVIE INC | 21.07 | 346.68B | ||
1ABBV.MI | ABBVIE INC | 20.82 | 342.48B | ||
AMG.DE | AMGEN INC | 16.43 | 161.21B | ||
1AMGN.MI | AMGEN INC | 15.84 | 160.89B | ||
1GILD.MI | GILEAD SCIENCES INC | 25.67 | 135.84B | ||
GIS.DE | GILEAD SCIENCES INC | 25.39 | 134.40B | ||
VX1.DE | VERTEX PHARMACEUTICALS INC | 1667.04 | 115.58B | ||
ARGX.BR | ARGENX SE | 253.61 | 33.75B | ||
22UA.DE | BIONTECH SE-ADR | N/A | 24.36B | ||
IDP.DE | BIOGEN INC | 9.25 | 20.54B | ||
1BIIB.MI | BIOGEN INC | 8.39 | 19.21B | ||
1MRNA.MI | MODERNA INC | N/A | 12.34B |
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Cambridge, Massachusetts and currently employs 5,600 full-time employees. The company went IPO on 2018-12-07. The firm is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). The company is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. Its diverse development pipeline consists of 45 therapeutic and vaccine programs, nine of which are in late-stage development. Its products include COVID-19 vaccines (mRNA-1273/Spikevax, next-generation mRNA-1283), RSV vaccine (mRNA-1345), Seasonal influenza vaccines (mRNA-1010, mRNA-1011, mRNA-1012, mRNA-1020 and mRNA-1030), Combination vaccines (mRNA-1083, mRNA-1230, mRNA-1045 and mRNA-1365), CMV vaccine (mRNA-1647), EBV vaccine (mRNA-1189 and mRNA-1195) and others.
MODERNA INC
325 Binney Street
Cambridge MASSACHUSETTS US
Employees: 5600
Company Website: https://www.modernatx.com/
Investor Relations: https://investors.modernatx.com/
Phone: 16177146500
The current stock price of 0QF.DE is 34.185 EUR. The price increased by 6.89% in the last trading session.
The exchange symbol of MODERNA INC is 0QF and it is listed on the Deutsche Boerse Ag exchange.
0QF.DE stock is listed on the Deutsche Boerse Ag exchange.
32 analysts have analysed 0QF.DE and the average price target is 53.2 EUR. This implies a price increase of 55.62% is expected in the next year compared to the current price of 34.185. Check the MODERNA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
MODERNA INC (0QF.DE) has a market capitalization of 13.19B EUR. This makes 0QF.DE a Large Cap stock.
MODERNA INC (0QF.DE) currently has 5600 employees.
MODERNA INC (0QF.DE) has a resistance level at 35.23. Check the full technical report for a detailed analysis of 0QF.DE support and resistance levels.
The Revenue of MODERNA INC (0QF.DE) is expected to decline by -31.86% in the next year. Check the estimates tab for more information on the 0QF.DE EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
0QF.DE does not pay a dividend.
MODERNA INC (0QF.DE) will report earnings on 2025-04-30, before the market open.
MODERNA INC (0QF.DE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-8.55).
ChartMill assigns a technical rating of 1 / 10 to 0QF.DE. When comparing the yearly performance of all stocks, 0QF.DE is a bad performer in the overall market: 98.16% of all stocks are doing better.
ChartMill assigns a fundamental rating of 4 / 10 to 0QF.DE. While 0QF.DE seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months 0QF.DE reported a non-GAAP Earnings per Share(EPS) of -8.55. The EPS increased by 25.22% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -25.18% | ||
ROE | -32.67% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 64% to 0QF.DE. The Buy consensus is the average rating of analysts ratings from 32 analysts.
For the next year, analysts expect an EPS growth of -6.83% and a revenue growth -31.86% for 0QF.DE